3rd European HIV Clinical Forum – Presentations

Break

TUESDAY, OCTOBER 24, 2017

 

Welcome, Introductions & Goals
by Program Chairs

 Session I
 

Boucher, Charles 2017State of the ART: Integrase Inhibitors Resistance
Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands

 

Schapiro Photo 2008State of the ART: Integrase Inhibitors (clinical overview) (not available)
Jonathan Schapiro, MD
Sheba Medical Center, Ramat Gan, Israel

 Session II
 Marcelin, Anne-Genevieve 2012 120x160What is the virological support for reduced drug regimens?
Anne-Geneviève Marcelin, PharmD, PhD
Pitié Salpêtrière Hospital, Paris, France
 Cooper, David 2015_120x160What is the clinical support for reduced drug regimens?
David Cooper, MD, DSc
University of New South Wales, Sydney, Australia
 

Can we use HIV reservoir assays to predict VF in simplification strategies? (not available)
Linos Vandekerckhove, MD, PhD
Ghent University Hospital, Ghent, Belgium

 Session III
 Mussini, Cristina 2017Clinical case presentation
Christina Mussini, MD
University of Modena and Reggio Emilia, Modena, Italy
 Oral abstract presentation
 Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a
Switching Regimen in HIV-TR Cohort.
D. Yağcı-Çağlayık, Turkey
 Dolutegravir used in real-life provides high rates of virological response
in conjunction with a rare emergence of integrase resistance.
D. Armenia, Italy
 French national survey of resistance to integrase inhibitors in a
context of routine hospital care (ANRS AC11 Virology Network).
A.G. Marcelin, France
 In-vitro selection of resistance mutations to dolutegravir outside
HIV-1 integrase.
O. Delelis, France
 Changes outside integrase in a patient failing on dolutegravir
maintenance monotherapy points to a new resistance
mechanism. (not available)
C. Lungu, The Netherlands
 Genetic variability of HIV-2 LTR regions impacts transcriptional
activities.
Q. Le Hingrat, France
 Serum cystatine as a marker for estimated glomerular filtration
rate (eGFR) assessment in HIV-1-infected patients with
dolutegravir-based antiretroviral therapy (ART).
R. Palich, France
 Evolution of bone mineral density and MDRD in HIV-infected
patients treated with dolutegravir based regimens: results at 48-
weeks
A. D'Avino, Italy
 Parczewski, Milosz 2015_120Clinical case presentation
Milosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
 Session IV
 Di Perri, Giovanni 2016 120x160One pill a day?: Integration novel delivery systems into routine care
Giovanni Di Perri, MD, PhD
University of Turin, Turin, Italy
 Lederman, Michael 2014_120Prospects of immunotherapy for treatment
Michael Lederman, MD
Case Western Reserve University, Cleveland, Ohio, USA